Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -259.86% | 140.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -259.86% | 140.66% | |||
| Cost of Revenue | -122.85% | 89.34% | |||
| Gross Profit | 121.87% | -81.93% | |||
| SG&A Expenses | -4.10% | -17.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -47.44% | 1.08% | |||
| Operating Income | 46.27% | 0.82% | |||
| Income Before Tax | 47.48% | -0.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.36% | -0.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.36% | -0.01% | |||
| EBIT | 46.27% | 0.82% | |||
| EBITDA | 46.32% | 0.84% | |||
| EPS Basic | 48.73% | 0.09% | |||
| Normalized Basic EPS | 34.41% | 0.10% | |||
| EPS Diluted | 48.84% | 0.00% | |||
| Normalized Diluted EPS | 34.41% | 0.10% | |||
| Average Basic Shares Outstanding | 0.74% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.74% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
